2017

150.00 rub.
Buy article
2017/№2

Cardioprotective therapy in patients with atrial fibrillation and heart failure with preserved ejection fraction (Pilot study)

Tatarsky B. A.1, Kazennova N. V.1, Arutyunov G. P.2
1 – Federal State Budgetary Institution "Federal Almazov North-West Medical Research Center" of the Ministry of Health of the Russian Federation, Akkuratova 2, St. Petersburg 197341
2 – Federal State Budgetary Educational Institution of Higher Education, "Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation, Ostrovityanova 1, Moscow 117997

Keywords: heart failure, atrial fibrillation, ranolazine

DOI: 10.18087/rhj.2017.2.2338

In the recent decade, there has been growing interest to the pathogenetic treatment of such a common combination as heart failure with preserved ejection fraction and atrial fibrillation. Apparently, heart failure with preserved ejection fraction reciprocally correlates with atrial fibrillation: atrial fibrillation results in heart failure while heart failure results in atrial fibrillation. Selection of protective, antiarrhythmic therapy for this category of patients is associated with considerable difficulties. This pilot study provided results of using an inhibitor of late sodium channel current, ranolazine, for treatment of recurrent atrial fibrillation in patients with CHF with preserved ejection fraction.
  1. Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. Circ Heart Fail. 2012;5(2):191–201. DOI:10.1161/CIRCHEARTFAILURE.111.965681.
  2. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920–5. DOI:10.1161/01.CIR.0000072767.89944.6E.
  3. Арутюнов А. Г., Рылова А. К., Арутюнов Г. П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (Павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал Сердечная Недостаточность. 2014;15(1):23–32 [Arutyunov A. G., Ry`lova A. K., Arutyunov G. P. Registr gospitalizirovanny`x paczientov s dekompensacziej krovoobrashheniya (Pavlovskij registr). Soobshhenie 1. Sovremennaya klinicheskaya xarakteristika paczienta s dekompensacziej krovoobrashheniya. Klinicheskie fenotipy` paczientov. Zhurnal Serdechnaya Nedostatochnost`. 2014;15(1):23–32].
  4. Арутюнов А. Г., Рылова А. К., Арутюнов Г. П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (регистр Павловской больницы). Сообщение 2. Клиническое значение и прогностическая роль некоторых параметров, определяемых при физикальном и инструментальном обследовании пациентов с декомпенсацией кровообращения. Журнал Сердечная Недостаточность. 2014;15(2):67–75 [Arutyunov A. G., Ry`lova A. K., Arutyunov G. P. Registr gospitalizirovanny`x paczientov s dekompensacziej krovoobrashheniya (registr Pavlovskoj bol`niczy`). Soobshhenie 2. Klinicheskoe znachenie i prognosticheskaya rol` nekotory`x parametrov, opredelyaemy`x pri fizikal`nom i instrumental`nom obsledovanii paczientov s dekompensacziej krovoobrashheniya. Zhurnal Serdechnaya Nedostatochnost`. 2014;15(2):67–75].
  5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI:10.1093/eurheartj/ehw128.
  6. Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL et al. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands. J Am Coll Cardiol. 2015;66(9):1000–7. DOI:10.1016/j.jacc.2015.06.1314.
  7. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36(46):3250–7. DOI:10.1093/eurheartj/ehv513.
  8. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.
  9. Sato N. Epidemiology of Heart Failure in Asia. Heart Fail Clin. 2015;11(4):573–9. DOI:10.1016/j.hfc.2015.07.009.
  10. Oluleye OW, Rector TS, Win S, McMurray JJV, Zile MR, Komajda M et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7(6):960–6. DOI:10.1161/CIRCHEARTFAILURE.114.001523.
  11. Linssen GCM, Rienstra M, Jaarsma T, Voors AA, van Gelder IC, Hillege HL et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2011;13(10):1111–20. DOI:10.1093/eurjhf/hfr066.
  12. Zakeri R , Borlaug BA, McNulty SE, Mohammed SF, Lewis GD, Semigran MJ et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail. 2014;7(1):123–30. DOI:10.1161/CIRCHEARTFAILURE.113.000568.
  13. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. DOI:10.1093/eurheartj/ehw210.
  14. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45. DOI:10.1093/eurheartj/ehl250.
  15. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF et al. Efficacy of β-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235–43. DOI:10.1016/S0140-6736(14)61373-8.
  16. Татарский Б. А. Использование блокатора поздних натриевых каналов при купировании пароксизмальной формы фибрилляции предсердий (пилотное исследование). Сердце: журнал для практикующих врачей. 2013;12(2):102–6 [Tatarskij B. A. Ispol`zovanie blokatora pozdnix natrievy`x kanalov pri kupirovanii paroksizmal`noj formy` fibrillyaczii predserdij (pilotnoe issledovanie). Serdcze: zhurnal dlya praktikuyushhix vrachej. 2013;12(2):102–6].
  17. Татарский Б. А. Протекторная терапия фибрилляции предсердий блокатором поздних натриевых каналов (пилотное исследование). Сердце: журнал для практикующих врачей. 2014;13(2):123–8 [Tatarskij B. A. Protektornaya terapiya fibrillyaczii predserdij blokatorom pozdnix natrievy`x kanalov (pilotnoe issledovanie). Serdcze: zhurnal dlya praktikuyushhix vrachej. 2014;13(2):123–8].
  18. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GYH, Schotten U et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429. DOI:10.1093/eurheartj/ehq278.
  19. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–40. DOI:10.1056/NEJMoa021375.
  20. Lam CSP, Rienstra M, Tay WT, Liu LCY, Hummel YM, van der Meer P et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. JACC Heart Fail. 2017;5(2):92–8. DOI:10.1016/j.jchf.2016.10.005.
  21. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539–50. DOI:10.1093/eurheartj/ehm037.
  22. Bers DM, Despa S. Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts. J Pharmacol Sci. 2006;100(5):315–22.
  23. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92 Suppl 4:iv6-iv14. DOI:10.1136/hrt.2005.078790.
  24. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013;1(2):115–22. DOI:10.1016/j.jchf.2012.12.002.
  25. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116(13):1449–57. DOI:10.1161/CIRCULATIONAHA.107.704890.
  26. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8(8):1281–90. DOI:10.1016/j.hrthm.2011.03.045.
  27. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled «research perspectives in atrial fibrillation». Europace. 2009;11(7):860–85. DOI:10.1093/europace/eup124.
  28. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110(8):904–10. DOI:10.1161/01.CIR.0000139333.83620.5D.
  29. Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol. 2009;54(4):279–86. DOI:10.1097/FJC.0b013e3181a1b9e7.
Tatarsky B. A., Kazennova N. V., Arutyunov G. P. Cardioprotective therapy in patients with atrial fibrillation and heart failure with preserved ejection fraction (Pilot study). Russian Heart Journal. 2017;16 (2):116–122

To access this material please log in or register

Register Authorize
Ru En